Terminal2 — Card #37: Alzheimer's Disease (Advanced)

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of advanced Alzheimer's disease at end of life. What the hospice team needs to understand on day one.

US Prevalence

~6.7M

Approximately 6.7 million Americans living with Alzheimer's dementia as of 2023. The most common cause of dementia, accounting for 60–80% of all cases. Prevalence rises steeply with age: ~5% aged 65–74, ~13% aged 75–84, and ~33% of people aged 85+. Projections exceed 12–13 million by 2050.^[1]

Disease Duration

8–10 yrs

Average duration from symptom onset to death is 8–10 years. Range is 3–20 years depending on age at onset, comorbidities, and care quality. Early-onset Alzheimer's (before age 65) tends toward longer survival. The hospice-eligible advanced stage at FAST 7 typically represents the final 1–2 years of a disease course that began years earlier.^[2]

FAST 7 Survival

6–12 mo

Median survival from FAST Stage 7A — speech limited to 1–5 words — is approximately 6–12 months with appropriate hospice care. Survival varies based on aspiration pneumonia frequency, nutritional status, skin integrity, and comorbid conditions. Some patients survive 18–24 months at FAST 7 with excellent care.^[3]

Leading Cause of Death

~70%

Aspiration pneumonia is the most common proximate cause of death in advanced Alzheimer's, accounting for approximately 70% of deaths. Other causes include sepsis from UTI or pressure wounds, cardiac events, and failure to thrive. Death certificates should reflect dementia as the primary diagnosis with aspiration pneumonia as the immediate cause.^[4]

Alzheimer's disease is a progressive neurodegenerative disorder caused by the accumulation of amyloid-beta plaques and tau neurofibrillary tangles in the brain, resulting in progressive neuronal loss and cortical atrophy. The clinical consequence is a relentless loss of cognitive function proceeding from memory impairment through personality change, language loss, executive dysfunction, loss of recognition of family, loss of ambulation, loss of swallowing, and ultimately death from aspiration pneumonia or systemic infection.^[5]

What distinguishes Alzheimer's from all other hospice diagnoses is not its clinical complexity at the terminal stage — which is relatively predictable — but its duration. The family at the bedside of a FAST 7F patient has often been grieving for 8 or 10 years. They have already buried the person they knew. What they are watching now is the final departure of a body that long outlived the person who inhabited it. The hospice clinician who understands this — who enters the home knowing that the grief is old and layered and not new — provides different care than the one who approaches this as a fresh crisis.^[6]

The clinical work in advanced Alzheimer's hospice centers on three things above all else: managing the aspiration risk that will end the patient's life, navigating the feeding tube decision that is the most common source of family conflict in all of hospice medicine, and assessing and treating discomfort in a patient who cannot speak and must be read through behavior.^[7]

🧭 Clinical framing

Alzheimer's disease is defined neuropathologically by amyloid-beta plaques and tau neurofibrillary tangles that destroy neurons progressively across cortical regions. The disease begins in the entorhinal cortex and hippocampus — explaining the early memory signature — and spreads relentlessly to association cortices and eventually all cortical regions. By FAST Stage 7, the brain has lost substantial cortical volume. The patient has lost speech, ambulation, the ability to sit independently, and eventually the ability to smile or hold their head up. The hospice clinician's role is not to treat the disease — there is no treatment for advanced Alzheimer's — but to manage the consequences of total cortical failure: dysphagia leading to aspiration, immobility leading to pressure wounds, inability to communicate leading to unrecognized pain, and the progressive shutdown of all voluntary function leading to death. The clinical challenge is not diagnostic uncertainty. It is managing comfort in a patient who cannot tell you what they feel, navigating the feeding tube debate with a family whose love makes them want to do something the evidence says will not help, and supporting a family whose grief has been building for a decade.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"When you walk into an advanced Alzheimer's home, the person in the hospital bed by the window hasn't spoken a recognizable word in 18 months. The spouse has been caring for them for a decade and is exhausted in a way that has no name. The adult children are fighting about whether to place a feeding tube because 'we can't just let her starve.' Your job is to sit down, slow everything down, and tell the truth — what the evidence actually says about feeding tubes, what this person would have wanted if they could still tell us, and what this family has actually been carrying, for all these years, without enough help. That conversation is the most important thing you will do on that visit. Maybe on any visit."

— Waldo, NP · Terminal2

S02Clinician

How It's Diagnosed

FAST staging as the primary hospice eligibility and trajectory framework. Most patients arrive with an established Alzheimer's diagnosis — this section helps you stage it, document it, and identify what to look for in the records.

The Functional Assessment Staging Tool (FAST) is the primary framework for staging Alzheimer's disease for hospice eligibility, prognostication, and trajectory documentation. Developed by Reisberg et al., it maps the progressive functional losses of Alzheimer's disease in an ordinal sequence that parallels the reverse order of normal childhood development. Hospice eligibility under the Medicare LCD requires FAST Stage 7A or beyond, plus one or more qualifying comorbid conditions in the prior 12 months.^[3]

FAST Staging Tool — Complete Framework

FAST Stage	Functional Description	Clinical Significance
Stage 1	No functional deficit — normal adult	No cognitive impairment detectable
Stage 2	Subjective functional deficit — forgets names, misplaces items	Subjective complaints, no objective findings; often dismissed as normal aging
Stage 3	Objective functional deficit — decreased job functioning, difficulty traveling to new locations	Noticeable to coworkers and family; may trigger diagnostic workup
Stage 4	Needs assistance with complex ADLs — managing finances, cooking, cleaning	Mild dementia; loss of executive function; driving becomes unsafe
Stage 5	Needs assistance with basic ADLs — dressing, bathing	Moderate dementia; needs daily caregiver support; personality changes prominent
Stage 6	Needs assistance with all ADLs — toileting, continence	Moderately severe dementia; incontinence develops; may not recognize family members
Stage 7A	Speech limited to approximately 1–5 intelligible words in a day	Hospice eligibility threshold (with comorbid conditions). Meaningful communication essentially lost. Median survival 6–12 months.^[3]
Stage 7B	All intelligible vocabulary lost	No recognizable words; may vocalize but without meaning; completely non-verbal
Stage 7C	Non-ambulatory — cannot walk without assistance	Wheelchair- or bed-bound; aspiration risk accelerating; pressure wound risk begins
Stage 7D	Cannot sit up independently	Requires total positioning support; contractures developing; feeding increasingly difficult
Stage 7E	Loss of ability to smile purposefully	Loss of emotional expression; families experience this as a profound milestone of loss
Stage 7F	Loss of ability to hold head up independently	Terminal stage; complete akinetic/mute state; death typically within weeks to months^[3]

🚨 Hospice Eligibility — FAST 7A+ Plus Comorbid Conditions

FAST Stage 7A alone is not sufficient for hospice eligibility under the Medicare LCD. The patient must also have experienced one or more of the following comorbid conditions in the past 12 months:

Aspiration pneumonia
Pyelonephritis or upper urinary tract infection
Septicemia
Decubitus ulcers — Stage 3 or 4
Recurrent fever despite antibiotic treatment
Inability to maintain adequate fluid and caloric intake — documented weight loss of ≥10% in prior 6 months or serum albumin <2.5 g/dL

Documentation note: FAST 7 sub-stages must be documented sequentially to demonstrate expected ordinal progression. A patient who skips stages or shows non-ordinal progression may warrant reconsideration of the Alzheimer's diagnosis — mixed dementia or other etiologies should be evaluated.^[8]

Neuroimaging & Assessment Tools

Neuroimaging: MRI or CT brain demonstrates cortical atrophy, hippocampal volume loss, and medial temporal lobe atrophy. At advanced stages, imaging typically shows severe diffuse cortical atrophy with enlarged ventricles (ex vacuo hydrocephalus). CT is adequate for hospice assessment purposes and for ruling out structural causes of acute decline such as subdural hematoma. MRI is more sensitive but rarely changes management in FAST 7 patients.^[9]

Neuropsychological testing is no longer applicable or feasible in FAST 7 patients who are non-verbal. MMSE, MoCA, and standard cognitive tests require verbal output and cannot be administered. The hospice clinician documents cognitive status by functional observation: number of words produced daily, ability to follow simple one-step commands, ability to make purposeful eye contact or facial expressions.

Behavioral pain assessment tools are critical for non-communicating advanced Alzheimer's patients. The PAINAD (Pain Assessment in Advanced Dementia) scale is the most validated and widely used tool — a 5-item scale scoring breathing, negative vocalization, facial expression, body language, and consolability on a 0–10 scale. A score of 4 or above warrants analgesic intervention. The Abbey Pain Scale is an alternative validated tool. Both are appropriate and should be used at every visit to document comfort status.^[10]

FAST Staging Framework

Guideline

Primary tool: Reisberg FAST — ordinal staging from 1 (normal) to 7F (terminal)
Key principle: Progression must be ordinal — document each sub-stage sequentially
Plateau risk: Some patients plateau at FAST 6 for extended periods before progressing
Non-ordinal progression: Suggests mixed dementia or alternative etiology — reconsider diagnosis
Documentation: Record FAST sub-stage at every recertification visit with specific functional observations

What to Look for in Hospice Records

Current FAST stage: Must be documented with sub-stage (7A, 7B, etc.)
Comorbid conditions: Aspiration pneumonia history, weight loss documentation, pressure wounds
Feeding method: Oral with modified texture, spoon-fed, or tube-fed; if PEG in place — document decision history and advance directive status
Advance directive status: POLST, DNR, specific guidance on artificial nutrition
Behavioral medication regimen: Antipsychotics, anxiolytics — doses and response
PAINAD scores: Documented at each visit with corresponding interventions
Skin integrity: Pressure wounds by stage and location
Caregiver status: Who is providing care, capacity, burnout risk, support in place

💡 For families

Your person's diagnosis of Alzheimer's disease was made before hospice enrollment — usually months or years before. The diagnostic workup is complete. What the hospice team does now is not diagnose the disease but track its progression using a tool called the FAST scale, which helps us understand where your person is in the disease course and what to expect next. The FAST scale measures what your person can still do — how many words they can speak, whether they can walk, sit up, or smile. This helps us plan the right level of care and support. We are not looking for a cure or a new diagnosis. We are focused entirely on your person's comfort and on supporting your family through this.

S03Everyone

Causes & Risk Factors

Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering the question families always ask: "Why did this happen?"

The amyloid cascade hypothesis remains the dominant explanatory framework for Alzheimer's disease. Amyloid-beta peptide accumulates extracellularly into plaques beginning 15–20 years before clinical symptoms appear. Tau protein hyperphosphorylation creates intraneuronal neurofibrillary tangles. Neuroinflammation, synaptic dysfunction, and progressive neuronal loss follow. The result is cortical atrophy that begins in the entorhinal cortex and hippocampus — explaining the early memory signature — and spreads to association cortices and eventually all cortical regions. By the time a patient reaches FAST 7, this process has devastated the brain over the course of decades.^[5]

Non-Modifiable Risk Factors

Age: The single strongest risk factor. Risk doubles approximately every 5 years after age 65. Approximately 33% of people aged 85+ are affected.^[1]
Family history: First-degree relative with Alzheimer's increases risk 2–3 fold
APOE ε4 allele: The most common genetic risk factor for late-onset Alzheimer's. One copy increases risk 2–3 fold; two copies increases risk 8–12 fold. Not deterministic — many carriers never develop Alzheimer's. Does not require routine genetic testing in most clinical settings.^[11]
Early-onset familial mutations: APP, PSEN1, PSEN2 — autosomal dominant, onset before age 65, accounts for <5% of all cases. These families require genetic counseling.^[12]
Sex: Women have higher lifetime risk, partly explained by longer life expectancy but evidence suggests sex-specific biological vulnerability beyond longevity
Down syndrome: Trisomy 21 — nearly universal development of Alzheimer's neuropathology by age 40 due to triplication of chromosome 21 including the APP gene^[13]

Modifiable Risk Factors — Lancet Commission 12

Meta-analysis

The Lancet Commission identified 12 modifiable risk factors that account for approximately 40% of all dementia cases globally:^[14]

Early life: Low educational attainment
Midlife: Hypertension, obesity, hearing loss, traumatic brain injury, excessive alcohol consumption
Later life: Depression, smoking, social isolation, physical inactivity, air pollution, diabetes

These factors are not clinically actionable for the hospice patient — they are referenced here because families ask about cause. The honest answer is that late-onset Alzheimer's is likely multifactorial, that genetics and modifiable factors both contribute, and that no one is responsible for their person's disease.

📊 Racial & Ethnic Disparities

Black Americans are approximately 2 times more likely to develop Alzheimer's dementia than white Americans. Hispanic Americans are approximately 1.5 times more likely. These disparities are driven by higher rates of cardiovascular risk factors, lower educational attainment linked to systemic inequality, reduced access to diagnosis and care, and diagnostic delay in communities with less access to specialty memory care. The diagnostic delay in communities of color means hospice enrollment often occurs later in the disease course with more established complications — pressure wounds, malnutrition, and untreated behavioral symptoms reflect the downstream effects of years of inadequate earlier care. The hospice clinician serving diverse communities must be aware of these disparities and adjust clinical assessment and communication accordingly.^[15]

❤️ For families: "Why did this happen?"

Families always ask this, and the honest answer matters. Late-onset Alzheimer's disease is caused by a combination of genetic factors, aging, and life exposures that interact over decades. There is no single cause that anyone could have prevented. Nothing your family did caused this. Nothing you failed to do would have prevented it. The disease began in your person's brain 15–20 years before the first symptoms appeared. The guilt that many families carry — "Should we have noticed sooner? Should we have done something differently?" — is understandable, but it is not supported by what we know about how this disease works. Your person's Alzheimer's disease is not anyone's fault.

⚕ Clinician note: Genetic counseling

Even at hospice enrollment, referral for genetic counseling is appropriate if early-onset familial Alzheimer's (onset before age 65) is identified or suspected — particularly in families with autosomal dominant patterns (APP, PSEN1, PSEN2 mutations). These mutations carry near-100% penetrance and affect multiple generations. Identifying them in surviving family members enables presymptomatic testing, clinical trial access, and reproductive planning. For late-onset Alzheimer's, APOE ε4 testing in family members is generally not recommended outside of research settings — the result is probabilistic, not deterministic, and can cause significant psychological distress without clear clinical benefit. If family members ask about genetic testing, refer to a genetic counselor rather than ordering testing directly.^[12]

S04ClinicianEveryone

Treatments & Procedures

Disease-modifying therapy context, prior medications the patient may have received, and the symptomatic management framework that defines all clinical work in advanced Alzheimer's hospice.

There is no disease-modifying therapy for advanced Alzheimer's disease. The FDA approved lecanemab (Leqembi) in 2023 and donanemab in 2024 — both anti-amyloid monoclonal antibodies — but these agents are indicated for mild cognitive impairment and early-stage Alzheimer's only. They have no role in advanced Alzheimer's (FAST 7). The hospice clinician must address them only if the family asks. The honest statement is: "These new medications are for the earliest stages of the disease and cannot help at this stage."^[16]

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine may have been prescribed earlier in the disease course. In advanced Alzheimer's at FAST Stage 7, evidence for benefit is absent and side effect burden is real — nausea, diarrhea, bradycardia, falls risk, nightmares. Reassess at enrollment: if there is no clear behavioral benefit being observed and the patient is FAST 7, a taper and discontinuation conversation with the prescribing physician is clinically appropriate.^[17]

Symptomatic Management — The Entire Clinical Focus

Feeding & Aspiration Management

The central clinical challenge in advanced Alzheimer's. The oral feeding approach is supported by all major palliative care and geriatrics society guidelines. PEG tube insertion does not improve survival, comfort, nutrition, aspiration risk, or quality of life in advanced dementia — the Cochrane review confirms this unambiguously. The hospice clinician must be completely fluent in this evidence and must communicate it clearly and compassionately to families.^[18]

Hand-feeding with modified texture and thickened liquids
Small amounts with appropriate positioning (upright ≥45°)
Goal is comfort and pleasure, not caloric sufficiency
A teaspoon of yogurt that gives pleasure is therapeutically valid

Behavioral Symptom Management (BPSD)

Behavioral and psychological symptoms of dementia affect up to 90% of patients at some stage — agitation, aggression, screaming, restlessness, repetitive behaviors.^[19]

First-line — non-pharmacological: Consistent routine, environmental modification, sensory stimulation, music therapy, validation, addressing unmet needs (pain, constipation, urinary retention, positioning discomfort)
Pharmacological: Quetiapine 12.5–50 mg BID as first-line antipsychotic; haloperidol 0.5–1 mg BID for refractory agitation
FDA black box warning: Antipsychotics in elderly with dementia carry increased mortality risk — must be disclosed and documented^[20]
Acute crises: Lorazepam or midazolam — use judiciously given paradoxical agitation risk with benzodiazepines

Pain Management in the Non-Communicating Patient

PAINAD score must drive the analgesic decision — use at every visit^[10]
First-line: Acetaminophen 500–1000 mg q6–8h scheduled (not PRN) for presumed pain in non-verbal patients
Evidence supports empirical scheduled acetaminophen for behavioral agitation in dementia patients when pain is suspected (Husebo et al. 2011)^[21]
Opioids: Morphine 2.5–5 mg q4h oral or SQ for moderate-to-severe pain by PAINAD or for dyspnea
Do not withhold opioids from an advanced dementia patient in distress because "they can't tell me they're in pain"

Dyspnea, Infection & Pressure Wound Management

Dyspnea: Morphine is the most evidence-supported agent; glycopyrrolate for secretions; positioning — HOB ≥30°; fan directed at face for air hunger
Aspiration pneumonia: Comfort-directed antibiotic decision must be explicit and values-based — antibiotics for comfort (fever, secretion, and dyspnea reduction) are different from antibiotics to cure^[22]
UTI: Common, symptomatic — treat for comfort
Pressure wounds: Repositioning every 2 hours; specialized mattress; nutritional support; wound care as comfort intervention — not healing intervention in advanced dementia^[23]

S05Clinician

When Therapy Makes Sense

Evidence-based criteria for comfort-directed interventions in advanced Alzheimer's. In this disease, "therapy that makes sense" is not about treating the disease — it is about treating the person inside it.

In advanced Alzheimer's disease, there is no disease-directed therapy. Every intervention is comfort-directed. The following are the evidence-supported clinical interventions that make sense at FAST Stage 7 — each one is grounded in published evidence, endorsed by major palliative care and geriatrics organizations, and aligned with the goal of maximizing comfort and dignity in the final phase of this disease.^[18]

01
Hand-feeding by a skilled and patient caregiver as the standard approach to nutrition. The evidence against PEG tube in advanced dementia is unambiguous — no survival benefit, no reduction in aspiration risk, no improvement in nutritional markers, no improvement in comfort or quality of life. The Cochrane review confirms this. Hand-feeding with modified texture and thickened liquids, offered in small amounts with appropriate positioning, is the comfort-aligned standard of care. The goal of hand-feeding at this stage is comfort and pleasure, not caloric sufficiency. A teaspoon of yogurt that gives pleasure is therapeutically valid even if the total daily intake is insufficient to maintain weight.^[18]
02
Scheduled PAINAD assessment at every visit with analgesic intervention at score ≥4. Empirical scheduled acetaminophen for patients with PAINAD scores indicating pain behavior. The PAINAD is not optional in a non-verbal advanced dementia patient — it is the stethoscope for suffering. A score that improves after scheduled acetaminophen is retrospective proof that pain was driving the behavioral symptom. Opioids for moderate-to-severe pain (PAINAD ≥6) or dyspnea — morphine 2.5–5 mg q4h.^[10]
03
Behavioral symptom management — non-pharmacological first-line, then pharmacological escalation. Consistent routine, environmental modification, individualized music therapy, validation approach, and addressing unmet physical needs (pain, constipation, urinary retention, positioning) before adding or increasing psychotropic medications. Document the non-pharmacological trial before the pharmacological escalation.^[19]
04
Comfort-directed antibiotic treatment for symptomatic aspiration pneumonia. Antibiotics given to reduce fever, secretions, and dyspnea are a comfort intervention and are appropriate in comfort-focused care. The family must understand the distinction: comfort-directed antibiotics treat symptoms, not disease trajectory. Frame explicitly: "We can use antibiotics to help with the fever and the breathing discomfort — that is a comfort goal."^[22]
05
Antipsychotic medication with explicit risk disclosure for refractory behavioral agitation. Quetiapine 12.5–50 mg BID or haloperidol 0.5–1 mg BID after non-pharmacological interventions and scheduled acetaminophen have been trialed. The FDA black box warning must be disclosed to the family and documented in the chart. The risk-benefit calculus favors antipsychotic use when behavioral agitation is causing clear suffering and has not responded to other interventions.^[20]
06
Pressure wound prevention — repositioning schedule, specialized mattress, and nutritional optimization within realistic limits. At FAST 7, immobility is complete or near-complete. Pressure wound prevention is a high-priority comfort intervention. Establish a 2-hour repositioning schedule, ensure an appropriate pressure-redistribution mattress is in place, and optimize nutrition within the limits of what the patient can safely accept by mouth.^[23]
07
Advance directive completion and POLST signing. If the patient does not have a current POLST or advance directive, the hospice enrollment is the moment to complete it with the healthcare proxy. This conversation must address: resuscitation status (CPR outcome data in advanced dementia is dismal — <1% survive to discharge), hospitalization preferences, artificial nutrition preferences, and antibiotic use preferences. Do not leave this to a later visit.^[24]
08
FAST staging documentation for certification and recertification. Accurate, sequential FAST sub-stage documentation is required for Medicare hospice eligibility. Document specific functional observations — number of words per day, ambulatory status, ability to sit independently, facial expression capability — at every recertification visit. Non-ordinal progression warrants diagnostic reconsideration.^[3]
09
Caregiver support assessment and intervention. The family caregiver of an advanced Alzheimer's patient has typically been providing care for years and is at high risk of caregiver burnout, depression, and complicated grief. Support services — respite care, caregiver support groups, counseling, and hospice aide visits — are therapeutically appropriate for the caregiver as part of the patient's plan of care. Screen the caregiver for depression and burnout at enrollment and at every recertification.^[25]

S06Clinician

When It Doesn't

Knowing when an intervention causes more harm than benefit is the most important clinical skill in advanced Alzheimer's hospice. The evidence is clear. The conversations are hard.

The interventions below are not recommended in advanced Alzheimer's disease at FAST Stage 7. The evidence against each is strong and the clinical consensus is clear. The hospice clinician must know this evidence and must be able to communicate it to families with clarity and compassion — not as opinion, but as what the research consistently shows.^[18]

01
PEG tube insertion in advanced Alzheimer's — FAST Stage 7. The evidence is unambiguous and the recommendation against PEG tube in this population is endorsed by the American Geriatrics Society, American Academy of Hospice and Palliative Medicine, and Society for Post-Acute and Long-Term Care Medicine. PEG does not improve survival, does not reduce aspiration risk (patients aspirate oral secretions regardless of feeding route), does not improve nutritional markers, and is associated with increased complications including tube-related pain, local infection, aspiration of tube feeds, and physical restraint to prevent tube removal. The hospice clinician must be able to say clearly and compassionately: "The research on feeding tubes in advanced dementia is very clear — they do not help people live longer or more comfortably, and they can cause additional discomfort. The approach that the evidence supports for your person is careful hand-feeding for comfort."^[26]^[27]
02
Hospitalization for aspiration pneumonia in a patient with comfort-only goals. Hospital admission results in exposure to new pathogens, physical restraint (IV lines, oxygen tubing, unfamiliar environment causing extreme agitation), separation from familiar caregivers, and aggressive diagnostic procedures that do not change management. Home management of aspiration pneumonia with comfort-directed antibiotics, antipyretics, morphine for dyspnea, and glycopyrrolate for secretions is the standard. This conversation must happen at enrollment, before the pneumonia occurs — not during it.^[22]
03
CPR and aggressive resuscitation in FAST 7 advanced Alzheimer's. The outcome data for CPR in advanced dementia is dismal. CPR in a nursing home or home setting results in survival to hospital discharge in less than 1% of cases in this population. Even a "successful" resuscitation results in ICU admission in a patient who cannot communicate, cooperate with care, or benefit from the life that is being prolonged. The family must be informed of this data explicitly and compassionately as part of advance directive and POLST completion.^[24]
04
Continuation of cholinesterase inhibitors and memantine in FAST Stage 7. No evidence of benefit at this stage. Realistic side effect burden includes nausea, diarrhea, bradycardia, falls risk, and nightmares. Taper and discontinue in consultation with the prescribing physician. The family may need reassurance: "These medications were appropriate earlier in the disease when they could still help. At this stage, they are no longer providing benefit, and stopping them will not change the course of the disease."^[17]
05
Aggressive wound care contradicting comfort goals. Surgical debridement, VAC therapy, or other aggressive wound interventions in a patient with advanced dementia and limited prognosis cause pain and distress without meaningful healing potential. Wound care at this stage is comfort-directed: keep the wound clean, manage odor, prevent infection, and minimize pain with dressing changes. Healing is not the goal — comfort is.^[23]
06
IV antibiotics at home for a patient with comfort-only goals. Oral or rectal antibiotics for comfort (fever and dyspnea reduction) are appropriate. IV antibiotics require vascular access, carry infection risk, and are associated with a curative rather than comfort intent. If the family's goal is comfort, oral or rectal routes achieve the same symptom palliation without the burden of IV access in a patient who will resist it.^[22]
07
Physical restraints for behavioral management. Restraints increase agitation, cause injury, violate dignity, and are never appropriate as a behavioral management tool in hospice care. If a patient is pulling at a PEG tube, catheter, or wound dressing, the correct response is to assess whether that device is still clinically appropriate — not to restrain the patient to preserve it.^[28]
08
Multiple antipsychotic agents at escalating doses without physical assessment. The behavioral symptom labeled as "agitation" may be driven by pain, constipation, urinary retention, a pressure wound, hunger, thirst, or an uncomfortable position. Treat the underlying cause before escalating antipsychotic doses. The PAINAD score should precede every antipsychotic dose increase. A complete physical assessment — including bladder scan, rectal exam if appropriate, skin check, and positioning review — is required before adding a second antipsychotic.^[21]

📋 Clinician note

The feeding tube conversation is the hardest conversation in advanced Alzheimer's hospice — harder than the DNR, harder than the prognosis discussion. The reason is that food carries emotional weight that no other medical intervention does. When a family says "we can't just let her starve," they are not making a medical argument. They are expressing love. The clinician who responds only with evidence has missed the point. The clinician who responds only with empathy has failed to inform. You must do both: hold the love completely — "I can see how much you love her, and I can see that this is terrifying" — and then deliver the evidence clearly — "What the research shows is that feeding tubes in advanced dementia do not help people live longer or more comfortably. The approach that helps most is careful hand-feeding for comfort." Do not leave the conversation ambiguous. The family needs a clear recommendation based on what the evidence actually shows, not a "it's your choice" handoff from a clinician who hasn't named what the research says.

S07Everyone

Out-of-the-Box Approaches

Evidence-graded integrative, interventional, and complementary approaches specific to advanced Alzheimer's. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.

Scheduled Empirical Acetaminophen for Behavioral Agitation

Grade A

Acetaminophen 500–1000 mg PO/liquid/suppository q6h (max 3 g/day)

The landmark Husebo et al. 2011 Lancet study demonstrated that scheduled acetaminophen 3 g/day significantly reduced agitation scores in nursing home patients with dementia. The mechanism: untreated pain presents as behavioral agitation in non-verbal dementia patients and is systematically under-recognized. The hospice clinician who interprets agitation as a psychiatric symptom and escalates antipsychotics without first treating for suspected pain has not followed the evidence. Scheduled acetaminophen is a first-line intervention for behavioral agitation in advanced dementia and should be documented as a pain management intervention, not just a comfort measure.^[21]

Individualized Music Therapy

Grade B

Personalized playlist — 30–60 min during care activities or agitation episodes

Personalized music — specifically music that was meaningful to the patient in their earlier life — has demonstrated reduction in agitation, anxiety, and behavioral symptoms in multiple RCTs in dementia. The mechanism likely involves preserved procedural and emotional memory pathways that survive longer than declarative memory in Alzheimer's disease. Playing the patient's preferred music during morning care, at mealtimes, and during periods of agitation is a low-cost, high-impact comfort intervention. Family members can identify the music; the hospice aide can implement it. Document it as a behavioral comfort intervention in the plan of care.^[29]

Simulated Presence Therapy

Grade C

Smartphone/tablet recording of family member's voice — play during agitation episodes

Recordings of a familiar family member's voice used to comfort an agitated non-verbal dementia patient. Small RCTs show reduction in agitation during playback. The mechanism parallels music therapy — preserved recognition of emotionally significant voices. Can be implemented with a smartphone recording of a family member speaking the patient's name and expressing love and reassurance. A low-burden, high-meaning intervention that families can provide themselves. Gives the family a sense of active contribution to comfort when they feel helpless.^[30]

Doll Therapy & Meaningful Object Use

Grade C

Realistic weighted doll or meaningful personal object — available during waking hours

Structured doll therapy — providing a realistic doll to a patient with advanced dementia — has demonstrated reduction in agitation and increase in calm, purposeful activity in small controlled studies. The mechanism activates preserved nurturing and attachment behaviors. Some families are uncomfortable with this approach initially — it may feel infantilizing. Frame it clinically: "This is not about treating your person like a child. It is about engaging a part of the brain that still works — the part that knows how to hold something and care for it." Not appropriate for all patients; some show no response or increased distress. Monitor and discontinue if not helpful.^[31]

Weighted Blanket Therapy

Grade C

10–15% of body weight blanket; 20–30 min during agitation or at sleep onset

Deep pressure stimulation via weighted blankets has shown modest reduction in anxiety and agitation in small dementia studies. The mechanism is similar to proprioceptive calming in other populations. Use with caution in patients who are very weak or have respiratory compromise — the weight must not restrict breathing. Monitor vital signs during initial use. Remove if the patient shows signs of distress or respiratory difficulty. Low-cost, easily implemented by family or hospice aide.^[32]

Light Therapy for Sundowning

Grade B

Bright light exposure (2,500–10,000 lux) for 30–60 min in the morning

Sundowning — increased agitation, confusion, and behavioral disturbance in late afternoon and evening — is among the most disruptive behavioral symptoms in Alzheimer's and among the most exhausting for caregivers. Morning bright light therapy has evidence for modest improvement in circadian rhythm dysregulation and reduction in sundowning severity. Can be implemented with a commercially available light therapy box positioned at the patient's eye level during morning care or breakfast. Combine with melatonin at bedtime for a circadian rhythm correction approach. Evidence strongest in patients who still have some visual function and daytime alertness.^[33]

Gentle Range-of-Motion Massage

Grade C

5–15 min gentle hand, foot, or extremity massage during care activities

Gentle tactile stimulation and passive range-of-motion exercises combined with massage have shown reduction in agitation and improvement in behavioral symptoms in small dementia studies. The mechanism is multifactorial — human touch, proprioceptive input, and contracture prevention. Particularly useful during bathing or dressing when agitation is common. Train the hospice aide and family in gentle technique. Avoid deep tissue massage or aggressive range-of-motion in patients with contractures — the goal is comfort, not rehabilitation. Document as a non-pharmacological behavioral intervention.^[34]

Namaste Care Program

Grade C

Structured daily program — 2–4 hours of multisensory engagement

Namaste Care is a structured program of multisensory stimulation designed specifically for patients with advanced dementia. It combines gentle touch, music, aromatherapy, verbal engagement, and environmental optimization (soft lighting, comfortable temperature, familiar scents) into a daily routine. Originally developed by Joyce Simard, the program has shown improvements in comfort indicators and reduction in behavioral symptoms in multiple observational studies and small RCTs. The hospice aide can be trained to deliver elements of the program. The core principle: even in the most advanced stage of dementia, the person is still there and still deserves engagement, not just custodial care. "The person is still in there" is not sentimentality — it is the clinical basis for this approach.^[35]

S08Everyone

Natural & Herbal Options

Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications. Families often bring supplements — this section helps you have the right conversation about what is safe in advanced Alzheimer's.

⚠️ Important Context

Advanced Alzheimer's disease has no effective disease-modifying therapy of any kind. The clinical focus at this stage is entirely on comfort, behavioral symptom management, and quality of the remaining time. Supplements in this context are adjuncts only — for agitation, sleep, general wellbeing, or caregiver-driven hope — and must be evaluated exclusively against the active comfort medication regimen. The primary safety concern in supplement selection for advanced Alzheimer's is the interaction with antipsychotics (quetiapine, haloperidol), benzodiazepines (lorazepam), and opioids. Anything that adds CNS sedation to this regimen increases fall risk in patients who are still ambulatory and respiratory depression risk in non-ambulatory patients. Additionally, in a patient who cannot communicate, any supplement side effect will manifest as behavioral change that may be misinterpreted as disease progression or pain. Keep the supplement regimen as simple as possible and disclose everything to the hospice team.

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Melatonin	Grade B	1–5 mg at bedtime; liquid formulation for swallowing difficulties	Sundowning and sleep-wake cycle dysregulation — modest evidence for improvement in nighttime wakefulness and sundowning severity; one of the most evidence-supported and lowest-risk supplements in this population^[36]	No significant interaction with quetiapine at standard doses. Mild drowsiness. Available in liquid form — important for patients with dysphagia. Monitor for next-day sedation.
Lavender Aromatherapy	Grade B	2–3 drops essential oil on collar/pillow or diffuser in room for 1–2 hours	Agitation reduction — Ballard et al. 2002 BMJ demonstrated significant reduction in agitation scores with lavender aromatherapy in dementia patients in a controlled trial^[37]	Non-systemic administration avoids drug interactions. Ensure no respiratory sensitivity (asthma, COPD). Stop if patient shows signs of distress or respiratory irritation. Do not apply undiluted oil to skin.
Chamomile	Grade C	Chamomile tea (1 cup) or extract 220–400 mg daily if tolerated orally	Mild anxiolytic and sleep aid — traditional use supported by small clinical trials showing modest reduction in generalized anxiety symptoms	May potentiate anticoagulant effects — monitor if on any blood thinners. Additive sedation with benzodiazepines. Allergic cross-reactivity in patients with ragweed allergy. Only appropriate if patient can still safely swallow thin liquids.
Lemon Balm (Melissa officinalis)	Grade C	300–600 mg extract daily or as tea	Mild anxiolytic and calming effects — small studies in dementia populations show modest reduction in agitation; may improve sleep quality	Theoretical interaction with thyroid medications. Mild sedative — additive with CNS depressants. Only for patients who can safely swallow. Monitor for gastrointestinal upset.
Ginkgo Biloba	Grade C	120–240 mg standardized extract daily	Limited evidence for cognitive benefit in mild-to-moderate dementia; no evidence for benefit in advanced Alzheimer's (FAST 7); families may ask about it based on earlier use	⚠ Critical note: Antiplatelet effect — increases bleeding risk. Contraindicated with anticoagulants. Interacts with CYP3A4 substrates. Not recommended at FAST 7 — no evidence of benefit at this stage and meaningful bleeding risk. If patient has been taking it, discuss discontinuation.
Vitamin E	Grade C	400–2000 IU daily (if continued from prior regimen)	One large RCT (TEAM-AD, 2014) showed modest delay in functional decline in moderate Alzheimer's at 2000 IU/day; no evidence of benefit in advanced disease	⚠ Contraindication at high doses: Increased all-cause mortality at doses >400 IU/day in meta-analysis. Anticoagulant effect — increases bleeding risk. If the patient has been taking high-dose vitamin E, the hospice enrollment is the appropriate time to discontinue it. Risk outweighs any theoretical benefit at FAST 7.^[38]
CBD Oil (Cannabidiol)	Grade C	5–25 mg sublingual BID; start low and titrate	Anecdotal and small-study evidence for agitation and sleep improvement in dementia populations; mechanism unclear; legal status varies by state	Inhibits CYP3A4 and CYP2D6 — may increase levels of quetiapine, haloperidol, opioids, and benzodiazepines. Additive CNS sedation. Verify legal status in your state. Quality and potency vary widely between products. If family is using or considering, the hospice team must know so that medication interactions can be monitored.

🚫 Avoid in Advanced Alzheimer's

St. John's Wort (Hypericum perforatum): Potent CYP3A4 inducer — reduces effectiveness of quetiapine, haloperidol, opioids, and benzodiazepines. Can precipitate serotonin syndrome if combined with any serotonergic agent. Contraindicated in any patient on antipsychotics or opioids — which includes virtually all advanced Alzheimer's hospice patients.
Kava (Piper methysticum): Hepatotoxicity risk — FDA warning. Profound additive CNS sedation with antipsychotics, benzodiazepines, and opioids. Respiratory depression risk in non-ambulatory patients. No clinical evidence for benefit in advanced dementia.
High-dose Vitamin E (>400 IU/day): Meta-analysis demonstrates increased all-cause mortality at high doses. Anticoagulant effect increases bleeding risk. No evidence of benefit in advanced Alzheimer's. Discontinue if currently prescribed.
Ginseng (Panax ginseng): Stimulant properties may exacerbate agitation and behavioral symptoms. Antiplatelet effects increase bleeding risk. Interacts with anticoagulants and antihypertensives. Not appropriate for advanced dementia patients whose primary clinical challenges are agitation and comfort management.

S09Everyone

Timeline Guide

A guide, not a prediction. Alzheimer's is the longest goodbye in medicine — the disease may span a decade before the body follows the mind. This timeline acknowledges that history while focusing on the hospice-relevant phases.

The Alzheimer's trajectory is unlike any other hospice diagnosis. By the time the patient reaches FAST 7 and meets hospice eligibility, the family has typically been providing escalating care for 5–10 years. The hospice enrollment visit is not the beginning of their journey — it is a late chapter in a story defined by progressive loss. The clinician who understands this history enters the relationship differently: not as a crisis responder, but as a companion joining a journey already well underway. Survival at FAST 7A is approximately 6–12 months, but some patients remain stable at FAST 7 sub-stages for 18–24 months with excellent comfort care.^[2] ^[26]

YRS–
MOS

Early-to-Moderate Decline — Pre-Hospice (FAST 1–6)

I know you've been doing this for a very long time. What we're starting today is not the beginning of this journey for you. It's a transition to a different kind of support at the end of it.
FAST 1–3: Subjective memory complaints → objective functional deficit → difficulty with complex tasks, driving, finances. Family begins assuming responsibilities. Duration: 2–4 years typical.
FAST 4–5: Needs assistance with complex then basic ADLs — dressing, bathing, meal preparation. Personality changes emerge — suspicion, withdrawal, repetitive behaviors. Family caregiving intensifies. Duration: 1–3 years.
FAST 6: Loss of continence, inability to toilet independently, requires 24-hour supervision. Recognition of familiar faces diminishes then disappears. This is the phase where families describe "losing" the person — the relationship itself transforms. Duration: variable, often 1–2 years.
Advance care planning should begin at diagnosis, not at FAST 6 — but frequently does not. By the time hospice arrives, many families have never had an honest prognostic conversation with a physician.

MOS–
WKS

Advanced Dementia FAST 7 — Early Hospice Phase

FAST 7A: Speech limited to approximately 1–5 intelligible words per day. This is the hospice eligibility threshold when accompanied by qualifying comorbid conditions.^[3]
FAST 7B: All intelligible vocabulary lost. Communication is reduced to grunting, moaning, or silence. Behavioral cues become the primary assessment language.
FAST 7C: Non-ambulatory — cannot walk without assistance. Fall risk is replaced by immobility-related complications: pressure injuries, contractures, pneumonia from decreased mobility.
Key clinical work in this phase: Advance directive and POLST completion with healthcare proxy. PEG tube discussion and resolution — this conversation must happen early, with evidence, and must not be deferred. Feeding protocol establishment (comfort hand-feeding). Pain assessment protocol using PAINAD. Behavioral symptom management plan. Caregiver training for aspiration precautions.
Prognosis: 6–12 months with appropriate hospice care. Some patients remain stable for 18–24 months. Co-morbid conditions — aspiration pneumonia, sepsis, pressure wounds — are required alongside FAST stage for hospice eligibility.^[26]

DAYS–
WKS

Late-Stage Decline — Active Deterioration

FAST 7D: Loss of ability to sit up independently. Patient becomes fully bed-bound. Repositioning schedule every 2 hours becomes critical for skin integrity.
FAST 7E: Loss of ability to smile purposefully. Social responsiveness diminishes. Family may interpret this as suffering — the clinical team must help them understand that the cortical capacity for voluntary facial expression has been lost.
FAST 7F: Loss of ability to hold head up independently. This represents near-total cortical loss. The patient is now in what is sometimes called the akinetic-mute state.
Weight loss becomes progressive and irreversible despite best feeding efforts. This is the disease, not a failure of nutrition. Document weight trends for recertification.
Aspiration events become more frequent. Low-grade fevers from micro-aspirations may become continuous. The family must already understand the aspiration pneumonia management plan before this phase arrives.
PAINAD becomes more critical as the patient loses all remaining behavioral communication. A score of 4+ requires immediate analgesic intervention — the quiet patient may be the one suffering most.^[11]

DAYS

Pre-Active Dying

Minimal responsiveness — patient may not react to voice, touch, or environmental stimuli. Eyes may remain partially open but unfocused.
Irregular breathing patterns emerge — periods of apnea alternating with rapid shallow respirations. This is central in origin, not distress.
Mottling begins on knees, feet, and dependent areas. Peripheral cyanosis may be visible in nail beds and earlobes.
Oral intake ceases entirely or is reduced to occasional drops of water or ice chips for mouth care comfort.
Urine output decreases significantly — dark, concentrated, or absent. This is a reliable marker of approaching death.
Family preparation: Describe exactly what they will see. Name the breathing changes. Name the skin changes. Tell them that hearing may persist even when all other responses have ceased. Give them permission to speak to their person, to say what needs to be said.^[26]

HRS

Final Hours

Cheyne-Stokes respiration — rhythmic crescendo-decrescendo breathing with apneic pauses. This may persist for hours. Family should know this pattern is expected and is not suffering.
Mandibular breathing — jaw-drop breathing with audible air movement. This typically indicates death within hours. It is a reliable marker.
No oral intake. Mouth care with moist swabs for comfort only. Suctioning only if secretions are distressing — the "death rattle" sounds worse to the family than it feels to the patient.
Aspiration pneumonia as the final event: In approximately 70% of advanced Alzheimer's deaths, the terminal event is aspiration pneumonia with progressive respiratory failure. The comfort medications should already be in place — morphine for dyspnea, glycopyrrolate for secretions, midazolam if terminal agitation develops.^[5]
Auditory awareness may persist even when all other responses have ceased. Encourage family to speak to their person. Play their music. Say the things that need to be said. The last sense to leave is hearing.
After death: Allow the family time. There is no rush. The body is not going anywhere. The family's grief did not begin today — but this is the moment when it changes shape.

S10Clinician

Medications to Anticipate

Symptom-targeted pharmacology for advanced Alzheimer's. Route transitions as swallowing fails, comfort kit preparation, and the decision tree for real-time clinical guidance.

⚠️ Route Transition Planning Is Critical

Advanced Alzheimer's medication management requires navigating two simultaneous challenges: managing a complex behavioral symptom regimen in a patient who cannot report whether the medications are helping, and planning ahead for the rapid route transitions that occur as swallowing fails. At enrollment, every oral medication must be assessed for availability in a non-oral formulation — liquid for PEG, sublingual, rectal, or subcutaneous — before the oral route fails. The comfort kit must be established and the family trained before any of the anticipated crises arrive: the aspiration pneumonia, the acute behavioral crisis, the terminal agitation. Anticipatory planning is the highest-value clinical skill in advanced Alzheimer's hospice.^[13]

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Acetaminophen	Analgesic / Empirical pain + fever	500–1000 mg PO/liquid/PR q6h SCHEDULED	The most important and most underused comfort medication in advanced dementia. Scheduled dosing — not PRN — for behavioral agitation where pain is suspected. Liquid formulation for PEG. Suppository for patients with no oral or PEG access. If behavioral agitation improves with scheduled acetaminophen, that is retrospective confirmation that pain was the driver. Husebo et al. 2011: scheduled acetaminophen significantly reduced agitation in nursing home dementia patients.^[13]
Morphine	Opioid / Pain + Dyspnea	2.5–5 mg PO liquid or SQ q4h + PRN	For dyspnea from aspiration pneumonia and moderate-to-severe pain by PAINAD. Must be in the home before the aspiration pneumonia arrives — prescribe at enrollment. Train family on dyspnea recognition and morphine administration before the crisis. Liquid oral morphine for patients who can still swallow; SQ for patients who cannot.^[11]
Quetiapine	Atypical antipsychotic / Agitation + Sundowning	12.5–50 mg PO/PEG BID-TID	For behavioral agitation, paranoia, sundowning. Liquid formulation available for PEG. Titrate slowly — start 12.5 mg QHS for sundowning, increase by 12.5 mg q3–5 days. ⚠ FDA BLACK BOX WARNING: Increased risk of death in elderly patients with dementia-related psychosis. Document informed consent with healthcare proxy. Risk-benefit discussion must be documented.^[16]^[17]
Haloperidol	Typical antipsychotic / Severe agitation + Delirium + Nausea	0.5–2 mg PO/SQ q4–8h	For severe agitation, delirium, nausea. SQ route available when oral route fails. More EPS risk than quetiapine — monitor for rigidity and akathisia. ⚠ Same FDA black box warning as quetiapine. Avoid in patients with Parkinsonism or Lewy body features. Preferred over quetiapine when SQ route is needed.^[16]
Lorazepam	Benzodiazepine / Anxiety	0.5–1 mg PO/SQ q4–6h PRN	For anxiety, not first-line for agitation. Benzodiazepines can paradoxically worsen confusion and agitation in dementia patients. Use cautiously. Reserve for anxiety with identifiable trigger. SQ route available. Paradoxical agitation more common in elderly dementia patients than in other hospice populations.
Glycopyrrolate	Anticholinergic / Terminal secretions	0.2 mg SQ q4h	Reduces terminal secretions without CNS effects. Preferred over hyoscine in patients with any residual consciousness. Does not cross blood-brain barrier. Anticipate need as aspiration pneumonia progresses.
Hyoscine patch	Anticholinergic / Secretions (transdermal)	1.5 mg patch q72h	Alternative for secretion management when SQ access is not available. Crosses blood-brain barrier — may cause or worsen confusion and agitation. Place behind ear. Takes 12–24 hours for full effect — not for acute management. Can use concurrently with glycopyrrolate during transition.^[26]
Atropine ophthalmic 1%	Anticholinergic / Secretions (sublingual)	1–2 drops SL q4h PRN	Off-label use for terminal secretions. Convenient sublingual administration. Family can administer. Faster onset than hyoscine patch. May cause dry mouth — provide mouth care. Keep in comfort kit.
Mirtazapine	Antidepressant / Depression + Insomnia + Appetite	7.5–15 mg PO QHS	Addresses depression, insomnia, and anorexia simultaneously — particularly valuable in advanced dementia. More sedating at lower doses (7.5 mg). Dissolving tablet formulation available for patients with dysphagia. Faster onset than SSRIs. Can reduce agitation associated with depression.^[26]
Metoclopramide	Prokinetic / Nausea	10 mg PO q6h	For nausea and gastroparesis. ⚠ Contraindicated with antipsychotics (quetiapine, haloperidol) — increased risk of EPS and tardive dyskinesia. If the patient is on an antipsychotic for agitation, use ondansetron for nausea instead. Not for bowel obstruction.
Midazolam	Benzodiazepine / Terminal agitation	2.5–5 mg SQ PRN	For terminal agitation and catastrophic symptom management. Must be in comfort kit pre-drawn and labeled. Goals-of-care discussion with family before initiating continuous infusion. Document clinical reasoning. Consider palliative sedation framework if refractory agitation requires continuous infusion (10–30 mg/24h).^[26]

🌿 Symptom Management Decision Tree

Evidence-based · Hospice-adapted · Alzheimer's-specific

Select a symptom below to begin

What is the primary symptom to address?

🚨 Comfort Kit Must-Haves for Advanced Alzheimer's

These medications must be in the home, drawn, labeled, and the family trained before the crisis arrives:

Aspiration pneumonia crisis: Morphine 5 mg/mL oral solution or SQ — for dyspnea. Glycopyrrolate 0.2 mg SQ — for secretions. Acetaminophen 650 mg suppository — for fever.
Acute behavioral crisis / terminal agitation: Haloperidol 1 mg SQ or Midazolam 2.5 mg SQ — drawn and labeled "For agitation: give SQ if unable to calm with non-pharmacologic measures."
Seizure (uncommon but possible in late-stage): Midazolam 5 mg SQ or Lorazepam 2 mg SQ — "Roll on side. Give medication. Call hospice."
Breakthrough pain: Morphine 2.5 mg SQ — for PAINAD score ≥4 when oral route unavailable.

Train the family on every medication before it is needed. Practice the SQ injection technique. Write the instructions in plain language on the syringe label. The 2 AM crisis is not the time to learn.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team managing advanced Alzheimer's. The things not in the textbook — learned at the bedside over years of clinical experience with this specific disease.

1

The PEG tube conversation must be led by evidence, not emotion

The hospice clinician who approaches the PEG tube decision in advanced Alzheimer's without complete fluency in the evidence is not prepared for the conversation. Know that PEG does not improve survival, does not reduce aspiration risk (patients aspirate oral secretions regardless), does not improve nutritional markers, and does not improve comfort in advanced dementia. Know the Cochrane review conclusion. Know the American Geriatrics Society 2014 position statement. Then lead the conversation from that evidence base while holding completely and respectfully the family's love and fear. The statement that works: "I want to share with you what the research shows, because I think you deserve accurate information when you're making this decision."^[6]^[7]^[8]

2

PAINAD at every visit — score 4+ requires analgesic intervention today

The PAINAD (Pain Assessment in Advanced Dementia) is not optional in a non-verbal advanced dementia patient. It is your stethoscope for suffering. A patient who scores 4 or above is in pain and requires an analgesic intervention — not at the next visit, today. A patient who is agitated and whose PAINAD score has not been formally assessed may be receiving antipsychotics for a behavioral symptom driven by untreated pain. Use the score. Document the score. Act on the score. Scheduled acetaminophen is the first-line response to a PAINAD above 4. A score that improves after scheduled acetaminophen is retrospective proof that pain was the driver.^[11]^[12]

3

Behavioral symptom assessment for unmet physical needs before escalating psychotropics

The behavioral symptom that does not respond to the current regimen must be assessed for unmet physical needs before the psychotropic is increased. Constipation, urinary retention, pain from a pressure wound, uncomfortable positioning, a full bladder, hunger, thirst, environmental noise — any of these will present as agitation in a non-verbal advanced dementia patient. Complete a physical assessment before increasing the antipsychotic dose. The checklist: palpate the bladder, check the diaper, examine the sacrum, assess the limb positioning, review the bowel record, check the room temperature, and evaluate for pain using the PAINAD. Only after ruling out reversible physical causes should the psychotropic regimen be escalated.^[15]

4

The aspiration pneumonia conversation must happen at enrollment — before the pneumonia

The family must know before the first aspiration pneumonia event: what aspiration pneumonia looks like (fever, increased secretions, respiratory distress, change in breathing pattern); that it is expected and likely — it is the most common cause of death in advanced Alzheimer's; that there are two approaches (comfort-directed management at home vs. hospital admission); and that the plan of care already accounts for it. When the conversation happens before the crisis, the family has space to process, ask questions, and decide. When it happens during the crisis at 2 AM with a fever of 103°F and audible congestion, the family panics and calls 911. The anticipatory conversation saves the patient from the ICU and saves the family from the guilt of a decision made in fear.^[5]^[9]

5

FAST staging must be accurate and ordinal for certification

FAST staging is the foundation of hospice eligibility documentation in Alzheimer's disease. The staging must be accurate, the sub-stages must be documented sequentially, and the expected ordinal progression must be demonstrated. A patient documented as FAST 7C (non-ambulatory) who was not first documented as 7A (limited speech) and 7B (no intelligible vocabulary) presents a documentation problem. Patients who skip stages or show non-ordinal progression may warrant reconsideration of the Alzheimer's diagnosis — mixed dementia, Lewy body dementia, or frontotemporal dementia may present differently. Document the FAST stage at every visit with supporting clinical observations.^[2]^[3]

6

Feeding should be pleasure-focused, not calorie-focused

In advanced Alzheimer's at FAST 7, the goal of feeding is comfort and pleasure, not caloric sufficiency or weight maintenance. A teaspoon of yogurt that gives pleasure is therapeutically valid even if the total daily intake is 200 calories. Hand-feeding with modified textures, offered in small amounts with appropriate positioning (upright, chin slightly tucked), is the comfort-aligned standard of care. The family who says "but they're not eating enough" needs to hear: "At this stage of the disease, the body is not able to process nutrition the way it used to. What we can do is offer food for comfort and pleasure — the taste, the sensation, the act of being fed by someone who loves them. That is the goal now." Document intake as comfort feeding, not nutritional intake.^[7]^[10]^[27]

7

The quiet patient may be the one suffering most

In a population that cannot verbalize pain, distress, or discomfort, silence is not the same as comfort. The patient who lies motionless and makes no sound may be in significant pain — the behavioral expression of pain in the most advanced stages of dementia can be withdrawal and immobility rather than vocalization and agitation. Use the PAINAD at every visit regardless of behavioral presentation. An empirical trial of scheduled acetaminophen in a quiet, withdrawn patient with advanced dementia is clinically appropriate and evidence-supported. If the patient becomes more alert, more responsive, or shows any improvement in affect or engagement after scheduled analgesia, pain was present and was being missed.

8

Route transition planning — assess every oral med for non-oral formulation

Swallowing fails progressively in advanced Alzheimer's — first for thin liquids, then for solids, then for thickened liquids, then for medications. At enrollment, assess every oral medication for availability in a non-oral formulation. Acetaminophen: liquid and suppository. Morphine: concentrated oral solution (20 mg/mL) and SQ. Quetiapine: liquid for PEG, but no SQ or sublingual — transition to haloperidol SQ when oral route fails. Lorazepam: sublingual or SQ. Mirtazapine: orally disintegrating tablet. Have the non-oral formulations identified and available before the oral route fails. The worst time to discover that a critical medication has no alternative route is the day the patient stops swallowing.

9

Racial and ethnic disparities in Alzheimer's care

Black Americans are approximately twice as likely and Hispanic Americans are approximately 1.5 times as likely to develop Alzheimer's dementia compared to non-Hispanic White Americans. Despite higher prevalence, Black and Hispanic Americans are diagnosed later, receive fewer disease-directed treatments, are more likely to receive PEG tubes in advanced dementia (contrary to evidence-based recommendations), are less likely to have advance directives, are less likely to be enrolled in hospice, and when enrolled, have shorter hospice length of stay. The clinician's role: recognize that historical medical mistrust, cultural values around family caregiving, religious beliefs about suffering and divine healing, and language barriers all affect decision-making. The response is not to impose a standard protocol but to provide full, transparent, culturally responsive information and to respect the family's decision-making process while ensuring they have access to the same evidence every family deserves.^[32]^[33]

10

Caregiver assessment is a clinical obligation — not an optional kindness

The family caregiver of an advanced Alzheimer's patient has typically been providing care for years — often decades — and is at extremely high risk of caregiver burnout, clinical depression (prevalence 30–40% in dementia caregivers), complicated grief, and physical health deterioration. Caregiver assessment should occur at every visit — not just at enrollment. Screen for depression using the PHQ-2. Ask about sleep. Ask about appetite. Ask about isolation. Ask about relief that cannot be named. The caregiver who says "I'm fine" while losing weight and not sleeping is not fine. Refer to social work proactively. Assess for respite care needs. Document caregiver status in the chart as a clinical finding, not just a social note.^[34]^[35]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The loudest patient is not always the sickest one. In Alzheimer's, the patient who is yelling and fighting you is communicating — they're telling you something is wrong. The patient who is silent and still? That's the one I worry about. Silence in a non-verbal dementia patient is not peace until you've proven it with a PAINAD score. Start the acetaminophen. Check back in 48 hours. If anything changes — anything at all — you just found pain that nobody was treating."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

The long goodbye, ambiguous loss, and the specific grief of a disease that steals the person years before the body dies. The symptom burden you can't see on a vitals sheet — and in Alzheimer's, it belongs to the family more than the patient.

Advanced Alzheimer's creates a form of grief that has no parallel in other hospice diagnoses. The family has watched their person leave in stages over years — first the personality, then the recognition, then the language, then the body. The term for this is ambiguous loss (Boss, 1999) — a loss without closure, without a clear moment of death, without the social permission to grieve because the person is still physically alive. The spouse who says "I already lost them years ago" is experiencing this ambiguous loss accurately. Acknowledge it directly: "What you are describing — feeling like you already lost your person even though they are still here — is a recognized and documented experience in families of people with dementia. It's called ambiguous loss and it is completely real. What you feel is not a betrayal and it is not a failure of love. It is an honest response to what dementia has taken."^[29]

The grief at a FAST 7 enrollment visit is typically 5–8 years old. The hospice enrollment is not the beginning of their grief — it is a milestone in a grief that predates this visit by half a decade or more. The hospice social worker and chaplain who understand this enter the relationship differently — not as crisis responders to a new loss, but as companions joining a journey already well underway.^[34]

Psychological Distress — The Family

Guilt, Role Strain & the Relief That Cannot Be Named

Grade B

Many family caregivers of advanced Alzheimer's patients experience relief as the end approaches — relief that the suffering and the burden are ending. This relief is almost universally experienced as guilt. The hospice chaplain and social worker must create space for relief to be named without judgment:

"Some people feel a kind of relief as their person gets closer to the end — relief that the suffering is ending, relief that the burden is lifting. And then they feel terrible about feeling relieved. Have you experienced any of that?"
Role strain in dementia caregiving is among the highest of all chronic diseases — the caregiver has often become parent to their parent, spouse to a stranger, guardian of someone who resists their care
Caregiver depression prevalence: 30–40%. Caregiver anxiety prevalence: 25–45%. These are clinical findings, not just social observations.^[34]^[35]

Identity Dissolution & Anticipatory Grief

Grade B

The patient's identity has already dissolved. They do not know who they are. They may not recognize their own reflection. The family is grieving not a dying person but a person already gone — a body that breathes but does not contain the person they loved.
The spouse's identity has dissolved too. They are no longer a wife or husband in any reciprocal sense. They are a caregiver to a person who does not know them. The loneliness of this position is profound.
Children and grandchildren: Adult children may be grieving a parent who does not recognize them. Grandchildren may never have known the person the family remembers. Both require age-appropriate support. Young children should be told the truth in simple language: "Grandma's brain is very sick. She may not remember your name, but she can feel your love."
Anticipatory grief in Alzheimer's is uniquely prolonged — it may last years before death and continues after death as complicated or prolonged grief in 20–30% of dementia caregivers.^[29]

Spiritual Assessment — Personhood & the Sacred

The spiritual questions in Alzheimer's are unlike any other diagnosis. They center on personhood itself: Is my person still "there"? Do they still have a soul if they don't know who they are? Does God hear the prayers of someone who can't form words? Is this suffering, or is this peace? These questions are not theological abstractions — they are the questions that keep family members awake at 3 AM. The hospice chaplain must be prepared to engage them directly and without false reassurance.

Use the FICA framework adapted for dementia families: Faith — "What sustains you through this?" Importance — "How important is your faith or spiritual life in coping with what's happening?" Community — "Is there a faith community that should know your family is going through this?" Address — "How can our team support you spiritually during this time?"^[26]

Clinical Pearl — The Question Behind the Question

"When a family member asks 'Is she still in there?' — they are not asking a medical question. They are asking a spiritual one. They want to know if their presence matters, if their person can still feel love, if the visits and the hand-holding and the music have any meaning at all. The answer — grounded in neuroscience and in clinical observation — is yes. Emotional processing pathways survive longer than cognitive ones. Touch, voice, music, and presence register even when recognition is gone. Say this to the family: 'The part of the brain that knows your voice and feels your hand — that part survives longer than the part that remembers your name. Your presence matters. Keep coming. Keep talking. Keep playing the music.'"

Goals-of-Care Communication

Alzheimer's-Specific Goals Conversations

"What would your person have wanted if they could tell us right now?" — redirects from the family's own fear to the patient's values
"When your person was well, did they ever say anything about how they'd want to be cared for if they couldn't care for themselves?" — elicits prior wishes
"What does a good day look like for your person now?" — redefines goals in terms of current reality, not past function
The PEG tube conversation is the central goals-of-care conversation in advanced Alzheimer's — it must not be avoided or deferred^[6]

Communication Pitfalls in Dementia

Don't say "they're comfortable" unless you have evidence — a PAINAD score. Comfort must be assessed, not assumed.
Don't say "they don't know what's happening" — families experience this as dismissive of their person's remaining humanity
Don't say "they had a good life" — the family is in grief; this minimizes their present suffering
Don't ask the family to "let go" — they have been losing this person for years; they do not need permission to grieve; they need companionship in it
Don't use the phrase "there's nothing more we can do" — in Alzheimer's, there is always more to do: comfort, presence, music, dignity, gentle care

Suicidal Ideation & Hastened Death Requests — Caregivers

In advanced Alzheimer's, the patient is not at risk for suicidal ideation — the cognitive capacity is absent. The caregiver is. Dementia caregivers have elevated rates of suicidal ideation, particularly those with caregiver depression, social isolation, and prolonged caregiving duration. Assess the caregiver directly: "This has been an incredibly long and exhausting journey. Some caregivers in your position have told me they've had thoughts of not wanting to go on. Have you experienced anything like that?" A "yes" requires immediate social work and psychiatric referral. Do not leave this to the next visit.^[34]

01
Name the ambiguous loss directly: Most families have never heard the term, but when they do, the relief is visible. "There is a name for what you're experiencing" — this single sentence validates years of unnamed grief.^[29]
02
Involve chaplaincy at enrollment, not at crisis: The spiritual questions in Alzheimer's are chronic and deep. They do not begin at the deathbed. They begin the day the person stops recognizing their spouse. Schedule chaplain visits routinely.
03
Support groups for dementia caregivers: Alzheimer's Association caregiver support groups are free, widely available, and evidence-based. Refer at enrollment. Online groups are available for homebound caregivers who cannot leave the patient.
04
Legacy work is different in dementia: The patient cannot participate in dignity therapy or life review. Legacy work in Alzheimer's is done by the family — creating memory books, recording family stories, preserving photographs. This is their grieving process and their healing.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The hardest grief I see in this work is in the spouses. They've been married fifty years and the person beside them doesn't know their name. They're not grieving a death — they're grieving an absence that has a pulse. I had a woman tell me once: 'I lost my husband five years ago. I'm just waiting for his body to catch up.' That's not bitterness. That's the most honest thing anyone has ever said to me about Alzheimer's. Name it. Make space for it. Don't rush past it."

— Waldo, NP · Terminal2

S13FamilyEveryone

Family Guide

Plain language for families caring for a person with advanced Alzheimer's. Share, print, or read aloud at the bedside. You are not alone in this.

You have been doing this for a long time. You have watched your person change in ways that no one can fully understand unless they have been through it. The person lying in that bed may not know your name anymore, but they are still your person — and you are still here, still showing up, still caring. That matters more than you know. This guide is written for you. It will help you understand what you may see in the days and weeks ahead, and how you can help your person be as comfortable as possible.

What You May See

Difficulty chewing or swallowing: Your person's brain is no longer sending the right signals to coordinate eating and swallowing safely. This is part of the disease, not a sign of inadequate care. Your nurse will show you how to feed safely and what signs of swallowing difficulty to watch for.
Coughing or choking during meals or liquids: This is the disease affecting the swallowing reflex. Call your nurse if this is happening frequently or getting worse. The nurse will review what is safe by mouth and help you adapt. Do not feel that you have failed if your person cannot eat well anymore.
Refusing food or not opening their mouth: Your person may not be hungry, may be fatigued, or may not be able to initiate eating. Offer food without pressure. Small amounts. Familiar foods. Stop when they resist. Forcing food increases the risk of choking and aspiration.
Changes in behavior — agitation, crying, hitting, or repetitive sounds: These behaviors are the disease expressing something your person cannot put into words. They may be in pain, uncomfortable, or frightened. Call your nurse, who will help assess and adjust medications. Do not assume this is simply the disease getting worse without first checking for a treatable cause.
Fever or new changes in breathing: This may be a sign of aspiration pneumonia, which is very common at this stage of the disease. Call your nurse immediately. You have a plan in place for this and it does not require an emergency room visit.
Increasing sleepiness and withdrawal: Your person may sleep most of the day. This is the disease progressing. Sit with them. Play their music. Speak to them. Your presence matters even without any visible response.

How You Can Help

Feed slowly, gently, and without pressure: Offer small bites of soft food on a small spoon. Wait for each swallow before offering the next bite. Stop when your person turns away, closes their mouth, or shows signs of fatigue. The goal is comfort and pleasure — not a certain number of calories.
Keep the head of the bed elevated during and after meals: Prop your person up at a 30–45 degree angle during feeding and for 30 minutes afterward. This reduces the risk of food entering the lungs.
Play their music: Music from your person's younger years — the songs they loved, the music that was important to them — can reach parts of the brain that the disease has not yet taken. Play it during meals, during care, and when they seem restless. It is one of the most powerful comfort tools you have.
Speak to them, even when they cannot respond: Your voice is familiar. It is comforting. Hearing may persist even when all other responses are gone. Talk to them about everyday things. Tell them who is in the room. Say the things you want them to hear.
Touch is therapeutic: Hold their hand. Stroke their hair. Gentle massage of the hands and feet can reduce agitation and provide comfort. Your touch says what words cannot.
Take care of yourself: You have been carrying this weight for years. Your health matters — not just for you, but for your person. Accept help when it is offered. Use the respite care your hospice provides. Call us when you need support — not just when your person does. You are part of this team.

🍽️ Feeding Guidance — Read Carefully

Hand-feeding is the right approach for your person at this stage. The research is very clear: a feeding tube (PEG tube) does not help people with advanced Alzheimer's live longer, does not reduce the risk of food entering the lungs, and does not improve comfort. What does help is gentle, patient hand-feeding — small amounts of soft food and thickened liquids offered for comfort and pleasure. If your person takes only a few spoonfuls a day, that is enough. The goal is not nutrition — it is the simple human comfort of tasting food and being fed by someone who loves them. If you have questions or concerns about feeding, please talk to your nurse or doctor. They can help you understand what is safe and what is comfortable.

📞 Call the nurse immediately if you see:

New fever above 101°F (38.3°C) — this may be aspiration pneumonia; your nurse has medications and a plan ready. Sudden difficulty breathing or noisy, wet breathing — do not call 911; call hospice first. Seizure activity — turn your person on their side, protect their head, give the medication your nurse showed you, and call hospice. Sudden change in responsiveness — your person is suddenly much more difficult to wake or completely unresponsive. Acute severe agitation that is not controlled by the medications you have — call for guidance on the next step. Fall or injury — especially if your person is still being transferred or repositioned. Bleeding from any source that does not stop with gentle pressure.

🙏 You are not just a caregiver. You are a companion to someone on the most difficult journey a human being can take. Research shows that patients whose families are present — talking, touching, playing music, simply being in the room — do better. Not just emotionally, but clinically. Your presence is medicine. The love you are giving right now, even when your person cannot acknowledge it, is the most important thing happening in that room. Thank you for being here.

S14Everyone

Waldo's Top 10 Tips

Clinical field wisdom from 12+ years at the bedside with advanced Alzheimer's patients and their families. Not guidelines — real talk from the field.

01

The PEG tube conversation is the most important conversation in advanced Alzheimer's hospice, and most clinicians avoid it or do it badly. Know the evidence cold before you walk in the door: PEG does not extend life in advanced dementia, does not reduce aspiration, does not improve nutrition, and does not improve comfort. The Cochrane review says it. The AGS says it. The data has been clear for twenty years. Lead with the evidence, hold the family's love, and do not leave the conversation ambiguous. The family needs a clear recommendation based on what the research actually shows — not a "it's your choice" handoff from a clinician who hasn't named what the science says. You can be compassionate and clear at the same time. In fact, you have to be.
02

Scheduled acetaminophen for agitation is one of the most important and most underused interventions in advanced dementia hospice. Before you increase the quetiapine, before you add a new antipsychotic, schedule the acetaminophen every 6 hours for 48 hours and see if the agitation changes. The Husebo study in The Lancet settled this in 2011 — scheduled analgesia significantly reduced agitation in nursing home dementia patients. And yet most hospice patients with dementia still arrive on zero scheduled analgesia. Fix that on day one. Acetaminophen 500–1000 mg q6h around the clock. It costs nothing, it hurts nothing, and if the agitation improves, you just saved this patient from an unnecessary antipsychotic and proved that pain was the driver all along.
03

Use the PAINAD score at every visit and write it in the chart. The PAINAD is not optional in a non-verbal advanced dementia patient — it is your stethoscope for suffering. A score of 4 or above means you give pain medication today, not at the next visit. A score that improves after scheduled acetaminophen is retrospective proof that pain was the driver. A score that does not improve tells you to escalate — maybe this is opioid-level pain, maybe it's a pressure wound, maybe it's a full bladder. Document it every time. If there's no PAINAD in the chart, there's no pain assessment. And if there's no pain assessment, there's no way to know if the patient in front of you is comfortable or silently suffering.
04

The behavioral symptom that is not responding to medication requires a physical assessment before the next psychotropic is added. Is the patient constipated? Does the bladder feel full? Is there a stage 2 wound developing over the sacrum? Is the diaper soaked and causing skin breakdown? Is the position causing pain in a contracted limb? Go through this list every single time the agitation is treatment-resistant. I have watched clinicians escalate antipsychotics three times before anyone palpated a bladder that was holding 800 mL of urine. A straight catheterization fixed the "treatment-resistant agitation" in ten minutes. Physical assessment before psychotropic escalation. Every time. No exceptions.
05

The aspiration pneumonia conversation must happen at enrollment — before the first pneumonia arrives. Here is what you say: "At this stage of the disease, pneumonia from food or saliva entering the lungs is very common. It is likely to happen at some point, and when it does, I want you to already have a plan. We have two approaches: we can manage it here at home with medications for fever, breathing, and comfort — which is what most families in this situation choose — or we can send your person to the hospital. I want to tell you honestly that the hospital usually involves IVs, X-rays, restraints, and a very frightening environment for a person with advanced dementia. Most of the time, our home approach works well and keeps your person comfortable." Have this conversation on week one. Not during the crisis.
06

Hand-feeding is comfort, not nutrition. This is the reframe that changes everything for families. They are terrified that their person is starving. They feel like they are failing because intake is dropping. Tell them: "At this stage, your person's body cannot process nutrition the way it used to. The feeding you are doing right now — those small bites, that sip of juice — that is comfort. The taste, the sensation, the human connection of being fed by someone who loves them. That is what matters. Not the calorie count." A teaspoon of ice cream that brings a flicker of pleasure is worth more than a can of Ensure that the patient aspirates. Redefine success. Document it as comfort feeding.
07

The music that survived the disease. I cannot tell you how many times I have walked into a room with a non-verbal, unresponsive advanced Alzheimer's patient — FAST 7E, no smile, no recognition, no language — and watched their face change when the family played their music. Not just any music. Their music. The songs from their twenties, their wedding song, the hymns from their church, the music that was the soundtrack of their lives. Procedural memory and emotional memory survive longer than any other cognitive function in Alzheimer's. The family who says "there's nothing left" has often not tried the music. Ask the family: "What music did your person love?" Get specific. Get the era right. Play it. Document it as a behavioral intervention. And when you see the response — the head turn, the humming, the tears — that is the disease-modified brain still responding to something that matters. That is the person, still there.
08

Racial disparities in Alzheimer's care are real, documented, and persistent — and the hospice clinician who does not acknowledge them is complicit in perpetuating them. Black Americans are twice as likely to develop Alzheimer's. Hispanic Americans are 1.5 times as likely. Both groups are diagnosed later, treated less aggressively in early stages, and paradoxically more likely to receive PEG tubes in advanced dementia — the one intervention the evidence says not to do. Both groups are less likely to enroll in hospice and have shorter lengths of stay when they do. The reasons are systemic: medical mistrust rooted in real historical harm, cultural values around family obligation and suffering, language barriers, and a healthcare system that has not earned the trust it demands. Your job is not to override these values. Your job is to provide full, transparent, culturally responsive information and to make hospice services as accessible and respectful as they should have been from the start.
09

Caregiver assessment at every visit — not just at enrollment. The caregiver of an advanced Alzheimer's patient has typically been providing care for 5–10 years. They are exhausted in a way that is qualitatively different from other hospice caregiver populations. They have watched their person disappear in slow motion. Many of them are clinically depressed and don't know it — or won't say it. At every visit, I ask three questions: "How are you sleeping?" "When was the last time you left the house for something that was just for you?" and "Is there anything you need to say to me that you haven't said yet?" The third question is the one that opens the door. The caregiver who breaks down and says "I don't know how much longer I can do this" is not weak. They are honest. Refer to social work. Arrange respite. Document caregiver distress as a clinical finding.
10

The person is still there. I know it doesn't look like it. I know the eyes are vacant and the words are gone and the face doesn't move. I know that from the outside, it looks like what's left is a body and nothing else. But I have been at enough bedsides, with enough advanced Alzheimer's patients, to tell you this with confidence: the person is still there. Not in the way they were before. Not in the way we measure personhood with language and recognition and memory. But in the way that a hand squeezed gently squeezes back. In the way the breathing changes when a familiar voice enters the room. In the way the agitation stops when the right music plays. Presence matters. Your presence matters. Keep showing up. Keep talking. Keep holding their hand. The last sense to leave is hearing. The last thing to die is the capacity to feel love. Be there for it.

— Waldo, NP

REFClinician

References

Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.

1

Alzheimer's Association. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598-1695.

PMID 36918389Report

2

Reisberg B. Functional Assessment Staging (FAST). Psychopharmacol Bull. 1988;24(4):653-659.

PMID 3249767Validation

3

Centers for Medicare & Medicaid Services. Local Coverage Determination: Hospice — Determining Terminal Status (Dementia). CMS LCD. L33393, revised 2022.

Guideline

4

Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136-1139.

PMID 7114305Validation

5

Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361(16):1529-1538.

PMID 19828530 DOIProspective Cohort

6

Sampson EL, Candy B, Jones L. Enteral tube feeding for older people with advanced dementia. Cochrane Database Syst Rev. 2009;(2):CD007209.

PMID 19370678 DOISystematic Review

7

American Geriatrics Society Ethics Committee and Clinical Practice and Models of Care Committee. American Geriatrics Society feeding tubes in advanced dementia position statement. J Am Geriatr Soc. 2014;62(8):1590-1593.

PMID 25039796Position Statement

8

Finucane TE, Christmas C, Travis K. Tube feeding in patients with advanced dementia: a review of the evidence. JAMA. 1999;282(14):1365-1370.

PMID 10527184Review

9

Hanson LC, Carey TS, Caprio AJ, et al. Improving decision-making for feeding options in advanced dementia: a randomized, controlled trial. J Am Geriatr Soc. 2011;59(11):2009-2016.

PMID 22091750RCT

10

Gillick MR. Rethinking the role of tube feeding in patients with advanced dementia. N Engl J Med. 2000;342(3):206-210.

PMID 10639550Review

11

Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9-15.

PMID 12807591Validation

12

Abbey J, Piller N, De Bellis A, et al. The Abbey Pain Scale: a 1-minute numerical indicator for people with end-stage dementia. Int J Palliat Nurs. 2004;10(1):6-13.

PMID 14966439Validation

13

Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065.

PMID 21765198 DOIRCT

14

Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.

PMID 25731881 DOIReview

15

Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.

PMID 22586419Review

16

FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. U.S. Food and Drug Administration. 2005; updated 2008.

Regulatory

17

Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943.

PMID 16234500Meta-analysis

18

Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476.

PMID 16437455Systematic Review

19

Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-854.

PMID 18519523RCT

20

McCleery J, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2020;11(11):CD009178.

PMID 33189083Systematic Review

21

van der Steen JT, Smaling HJA, van der Wouden JC, Bruinsma MS, Scholten RJPM, Vink AC. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018;7(7):CD003477.

PMID 30033623 DOISystematic Review

22

Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002;63(7):553-558.

PMID 12143909RCT

23

Garland K, Beer E, Eppingstall B, O'Connor DW. A comparison of two treatments of agitated behavior in nursing home residents with dementia: simulated family presence and preferred music. Am J Geriatr Psychiatry. 2007;15(6):514-521.

PMID 17545451RCT

24

Abraha I, Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open. 2017;7(3):e012759.

PMID 28302633Systematic Review

25

Music & Memory Inc. Personalized music for people with dementia: evidence summary. musicandmemory.org. 2021.

Program Report

26

Mitchell SL. Advanced dementia. N Engl J Med. 2015;372(26):2533-2540.

PMID 26107053 DOIReview

27

Palecek EJ, Teno JM, Casarett DJ, Hanson LC, Rhodes RL, Mitchell SL. Comfort feeding only: a proposal to bring clarity to decision-making regarding difficulty with eating for persons with advanced dementia. J Am Geriatr Soc. 2010;58(3):580-584.

PMID 20398123Expert Consensus

28

Simard J, Volicer L. Effects of Namaste Care on residents who do not benefit from usual activities. Am J Alzheimers Dis Other Demen. 2010;25(1):46-50.

PMID 19276095Observational

29

Boss P. Ambiguous Loss: Learning to Live with Unresolved Grief. Cambridge, MA: Harvard University Press; 1999.

Book

30

van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.

PMID 36449413 DOIRCT

31

Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527.

PMID 37459141 DOIRCT

32

Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.

PMID 32738937 DOICommission Report

33

Lines LM, Sherif NA, Wiener JM. Racial and ethnic disparities among individuals with Alzheimer's disease in the United States: a literature review. RTI Press. 2014.

PMID 27685529Review

34

Schulz R, Martire LM. Family caregiving of persons with dementia: prevalence, health effects, and support strategies. Am J Geriatr Psychiatry. 2004;12(3):240-249.

PMID 15126224Review

35

Pinquart M, Sörensen S. Differences between caregivers and noncaregivers in psychological health and physical health: a meta-analysis. Psychol Aging. 2003;18(2):250-267.

PMID 12825775Meta-analysis

36

Xu J, Wang LL, Dammer EB, et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015;30(5):439-447.

PMID 25614508Meta-analysis

37

Holmes C, Hopkins V, Hensford C, MacLaughlin V, Wilkinson D, Rosenvinge H. Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. Int J Geriatr Psychiatry. 2002;17(4):305-308.

PMID 11994882RCT

38

Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33-44.

PMID 24381967RCT

39

Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.

PMID 8346443Epidemiological

40

Teno JM, Gozalo PL, Mitchell SL, et al. Does feeding tube insertion and its timing improve survival? J Am Geriatr Soc. 2012;60(10):1918-1921.

PMID 23002947Observational

41

Givens JL, Jones RN, Shaffer ML, Kiely DK, Mitchell SL. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med. 2010;170(13):1102-1107.

PMID 20625013Observational

42

Volicer L, Hurley AC, Blasi ZV. Characteristics of dementia end-of-life care across care settings. Am J Hosp Palliat Care. 2003;20(3):191-200.

PMID 12785040Observational

43

Teno JM, Mitchell SL, Kuo SK, et al. Decision-making and outcomes of feeding tube insertion: a five-state study. J Am Geriatr Soc. 2011;59(5):881-886.

PMID 21539524Observational

44

Arcand M. End-of-life issues in advanced dementia: part 1: goals of care, decision-making process, and a practical approach to feeding problems. Can Fam Physician. 2015;61(4):330-334.

PMID 25873700Review

45

Arcand M. End-of-life issues in advanced dementia: part 2: management of poor nutritional intake, dehydration, and pneumonia. Can Fam Physician. 2015;61(4):337-341.

PMID 25873701Review

46

Sachs GA, Shega JW, Cox-Hayley D. Barriers to excellent end-of-life care for patients with dementia. J Gen Intern Med. 2004;19(10):1057-1063.

PMID 15482560Review

47

Hendriks SA, Smalbrugge M, Hertogh CM, van der Steen JT. Dying with dementia: symptoms, treatment, and quality of life in the last week of life. J Pain Symptom Manage. 2014;47(4):710-720.

PMID 23916680Observational

48

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.

PMID 27025652Review

49

Brodaty H, Donkin M. Family caregivers of people with dementia. Dialogues Clin Neurosci. 2009;11(2):217-228.

PMID 19585957Review

50

Sampson EL, Burns A, Richards M. Improving end-of-life care for people with dementia. Br J Psychiatry. 2011;199(5):357-359.

PMID 22045943Editorial

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — saved to your browser only. Not transmitted to any server.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.